Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11331289 | 0.85 | ALDH1A1 (0.45) | TDP1TSHRMRGPRX4 | |
| SCHEMBL5541035 | 0.81 | MRGPRX4 (0.47) | TDP1TSHRMRGPRX4S1PR4HPGD | |
| SCHEMBL11090538 | 0.81 | TDP1 (0.53) | TDP1TSHRMAPTSMN1; SMN2S1PR4 | |
| SCHEMBL3434867 | 0.81 | KDM4E (0.50) | TSHRMRGPRX4MAPTSMN1; SMN2HTT | |
| SCHEMBL27565960 | 0.81 | NPC1 (0.48) | TDP1MAPTSMN1; SMN2S1PR4GAA | |
| SCHEMBL3638624 | 0.81 | HPGD (0.58) | TDP1TSHRMRGPRX4MAPTS1PR4 | |
| SCHEMBL11028837 | 0.81 | MRGPRX4 (0.53) | TDP1TSHRMRGPRX4S1PR4HPGD | |
| SCHEMBL11223887 | 0.80 | MAPT (0.55) | TDP1TSHRMAPTSMN1; SMN2S1PR4 | |
| SCHEMBL96583 | 0.79 | MAPT (0.54) | TDP1TSHRMAPTSMN1; SMN2S1PR4 | |
| SCHEMBL11228073 | 0.78 | TDP1 (0.53) | TDP1TSHRMRGPRX4MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021082901-A1 | PHENYLISOXAZOLINE COMPOUND AND USE THEREOF | 沈阳中化农药化工研发有限公司 | 2021-05-06 | — | — | WO | claimed |
| CN-112745269-A | Phenyl isoxazoline compound and application thereof | 沈阳中化农药化工研发有限公司 | 2021-05-04 | — | — | CN | claimed |
| CN-105777640-B | Pyrazole cyclohexanediol ether compound and application thereof | 沈阳中化农药化工研发有限公司 | 2020-01-07 | — | — | CN | claimed |
| CN-105777640-A | Pyrazole cyclohexanediol ether compounds and applications thereof | 沈阳中化农药化工研发有限公司 | 2016-07-20 | — | — | CN | claimed |
| EP-2248820-B1 | Universal supports for oligonucleotide synthesis | GLEN RES CORP (US) | 2014-01-08 | — | — | EP | claimed |
| EP-1945798-B1 | METHOD FOR DETERMINING THE CLEAVABILITY OF SUBSTRATES | FORSCHUNGSZENTRUM BORSTEL (DE) | 2013-05-22 | — | — | EP | claimed |
| EP-1404695-B1 | UNIVERSAL SUPPORTS FOR OLIGONUCLEOTIDE SYNTHESIS | GLEN RES CORP (US) | 2013-04-10 | — | — | EP | claimed |
| EP-2248820-A1 | Universal supports for oligonucleotide synthesis | Glen Research Corporation (US) | 2010-11-10 | — | — | EP | claimed |
| US-20090258381-A1 | Methods for Determining the Cleavability of Substrates | FORSCHUNGSZENTRUM BORSTEL (DE) | 2009-10-15 | — | — | US | claimed |
| US-7491817-B2 | Universal supports for oligonucleotide synthesis | GLEN RESEARCH CORPORATION (US) | 2009-02-17 | — | — | US | claimed |
| EP-1404695-A2 | UNIVERSAL SUPPORTS FOR OLIGONUCLEOTIDE SYNTHESIS | Glen Research Corporation (US) | 2004-04-07 | — | — | EP | claimed |
| US-20020137855-A1 | Universal supports for oligonucleotide synthesis | GLEN RESEARCH CORPORATION (US) | 2002-09-26 | — | — | US | claimed |
| WO-2002044398-A2 | UNIVERSAL SUPPORTS FOR OLIGONUCLEOTIDE SYNTHESIS | GLEN RESEARCH CORPORATION (US) | 2002-06-06 | — | — | WO | claimed |
| EP-0675895-B1 | ETOPOSIDE DERIVATIVES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A DRUG AND IN THE PREPARATION OF A DRUG FOR TREATING CANCER | PF MEDICAMENT (FR) | 1997-07-23 | — | — | EP | claimed |
| US-5643885-A | Etoposide derivatives, process for preparing them, their use as a medicinal product and their use for the preparation of a medicinal product intended for anti-cancer treatment | PIERRE FABRE MEDICAMENT (FR) | 1997-07-01 | — | — | US | claimed |
| JP-H08504795-A | — | — | 1996-05-21 | — | — | JP | claimed |
| EP-0324917-B1 | LOW PLATE-OUT POLYCARBONATES | GENERAL ELECTRIC COMPANY (US) | 1993-06-30 | — | — | EP | claimed |
| EP-0324917-A1 | Low plate-out polycarbonates | GENERAL ELECTRIC COMPANY (US) | 1989-07-26 | — | — | EP | claimed |
| US-4841015-A | Low plate-out polycarbonate end capped with phenoxy acetic acid | GENERAL ELECTRIC COMPANY (US) | 1989-06-20 | — | — | US | claimed |
| US-4554011-A | Herbicidal 2S-(2β,4β,5β)-5-Arylmethoxy-4-substituted 2-alkyl-1,3-dioxane derivatives | CHEVRON RESEARCH COMPANY (US) | 1985-11-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137855-A1 | Universal supports for oligonucleotide synthesis | FBL, NSUN2, NOP2 | TDP1 1148/4885TSHR 3476/4885MRGPRX4 2020/4885 |
| US-20090258381-A1 | Methods for Determining the Cleavability of Substrates | CTSF, ADAM17, ADAM10 | TDP1 587/4885TSHR 3614/4885MRGPRX4 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.